188 related articles for article (PubMed ID: 33613700)
21. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.
Gougis P; Carton M; Tchokothe C; Campone M; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Bachelot T; Hennequin A; Perrin C; Gonçalves A; Uwer L; Eymard JC; Petit T; Mouret-Reynier MA; Chamorey E; Simon G; Saghatchian M; Cailliot C; Le Tourneau C
Breast; 2020 Feb; 49():17-24. PubMed ID: 31675683
[TBL] [Abstract][Full Text] [Related]
22. Real-world evidence of the management and prognosis of young women (⩽40 years) with
Mallet A; Lusque A; Levy C; Pistilli B; Brain E; Pasquier D; Debled M; Thery JC; Gonçalves A; Desmoulins I; De La Motte Rouge T; Faure C; Ferrero JM; Eymard JC; Mouret-Reynier MA; Patsouris A; Cottu P; Dalenc F; Petit T; Payen O; Uwer L; Guiu S; Frenel JS
Ther Adv Med Oncol; 2022; 14():17588359211070362. PubMed ID: 35082924
[TBL] [Abstract][Full Text] [Related]
23. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).
Pérol D; Robain M; Arveux P; Mathoulin-Pélissier S; Chamorey E; Asselain B; Berchery D; Gourgou S; Breton M; Delaine-Clisant S; Mons M; Diéras V; Carton M; Guizard AV; Laborde L; Laurent C; Loeb A; Mouret-Reynier MA; Parent D; Perrocheau G; Campion L; Velten M; Cailliot C; Ezzalfani M; Simon G
BMJ Open; 2019 Feb; 9(2):e023568. PubMed ID: 30796119
[TBL] [Abstract][Full Text] [Related]
24. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
Pasquier D; Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Petit A; Mouret-Reynier MA; Goncalves A; Dalenc F; Deluche E; Fresnel JS; Augereau P; Ferrero JM; Geffrelot J; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Mouttet-Audouard R; Bachelot T; Courtinard C
Eur J Cancer; 2020 Jan; 125():22-30. PubMed ID: 31835235
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort.
Grinda T; Joyon N; Lusque A; Lefèvre S; Arnould L; Penault-Llorca F; Macgrogan G; Treilleux I; Vincent-Salomon A; Haudebourg J; Maran-Gonzalez A; Charafe-Jauffret E; Courtinard C; Franchet C; Verriele V; Brain E; Tas P; Blanc-Fournier C; Leroux A; Loussouarn D; Berghian A; Brabencova E; Ghnassia JP; Scoazec JY; Delaloge S; Filleron T; Lacroix-Triki M
NPJ Breast Cancer; 2021 Apr; 7(1):41. PubMed ID: 33863896
[TBL] [Abstract][Full Text] [Related]
26. Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients.
Taskindoust M; Thomas SM; Sammons SL; Fayanju OM; DiLalla G; Hwang ES; Plichta JK
Ann Surg Oncol; 2021 Nov; 28(12):7441-7449. PubMed ID: 34050430
[TBL] [Abstract][Full Text] [Related]
27. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Mailliez A; D'Hondt V; Lusque A; Caron O; Cabel L; Goncalves A; Debled M; Gladieff L; Ferrero JM; Petit T; Mouret-Reynier MA; Eymard JC; Levy C; Uwer L; Leheurteur M; Desmoulins I; Bachelot T; Frenel JS; de la Motte Rouge T; Simon G; Jacot W; Delaloge S
Int J Cancer; 2023 Mar; 152(5):921-931. PubMed ID: 36161271
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
[TBL] [Abstract][Full Text] [Related]
29. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
30. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.
Cabel L; Carton M; Pistilli B; Dalenc F; Vanlemnens L; Levy C; Jacot W; Debled M; Loeb A; Hennequin A; De la Motte Rouge T; Laborde L; Laurent C; Chamorey E; Parent D; Petit T; Mouret-Reynier MA; Campone M; Perrocheau G; Labreveux C; Bachelot T; Robain M; Lerebours F
Breast; 2021 Apr; 56():18-25. PubMed ID: 33561617
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database.
Carausu M; Carton M; Cabel L; Patsouris A; Levy C; Verret B; Pasquier D; Debled M; Gonçalves A; Desmoulins I; Lecouillard I; Bachelot T; Ferrero JM; Eymard JC; Mouret-Reynier MA; Chevrot M; De Maio E; Uwer L; Frenel JS; Leheurteur M; Petit T; Darlix A; Bozec L
Ther Adv Med Oncol; 2022; 14():17588359221077082. PubMed ID: 35237352
[TBL] [Abstract][Full Text] [Related]
32. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Jacot W; Heudel PE; Fraisse J; Gourgou S; Guiu S; Dalenc F; Pistilli B; Campone M; Levy C; Debled M; Leheurteur M; Chaix M; Lefeuvre C; Goncalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Courtinard C; Cottu P; Robain M; Mailliez A
Int J Cancer; 2019 Dec; 145(12):3359-3369. PubMed ID: 31087564
[TBL] [Abstract][Full Text] [Related]
33. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
34. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
Wedam SB; Beaver JA; Amiri-Kordestani L; Bloomquist E; Tang S; Goldberg KB; Sridhara R; Ibrahim A; Kim G; Kluetz P; McKee A; Pazdur R
J Clin Oncol; 2018 Apr; 36(12):1225-1231. PubMed ID: 29522361
[TBL] [Abstract][Full Text] [Related]
35. Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.
Pons-Tostivint E; Kirova Y; Lusque A; Campone M; Geffrelot J; Mazouni C; Mailliez A; Pasquier D; Madranges N; Firmin N; Crouzet A; Gonçalves A; Jankowski C; De La Motte Rouge T; Pouget N; de La Lande B; Mouttet-Boizat D; Ferrero JM; Uwer L; Eymard JC; Mouret-Reynier MA; Petit T; Robain M; Filleron T; Cailliot C; Dalenc F
Ann Surg Oncol; 2019 Feb; 26(2):356-365. PubMed ID: 30539492
[TBL] [Abstract][Full Text] [Related]
36. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
[TBL] [Abstract][Full Text] [Related]
37. Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
Hotton J; Lusque A; Leufflen L; Campone M; Levy C; Honart JF; Mailliez A; Debled M; Gutowski M; Leheurteur M; Goncalves A; Jankowski C; Guillermet S; Bachelot T; Ferrero JM; Eymard JC; Petit T; Pouget N; de La Lande B; Frenel JS; Villacroux O; Simon G; Pons-Tostivint E; Marchai F
Ann Surg; 2023 Jan; 277(1):e153-e161. PubMed ID: 33534229
[TBL] [Abstract][Full Text] [Related]
38. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.
Frank S; Carton M; Dubot C; Campone M; Pistilli B; Dalenc F; Mailliez A; Levy C; D'Hondt V; Debled M; Vermeulin T; Coudert B; Perrin C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Patsouris A; Guesmia T; Bachelot T; Robain M; Cottu P
Breast; 2020 Aug; 52():50-57. PubMed ID: 32380440
[TBL] [Abstract][Full Text] [Related]
39. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
40. Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
Heudel P; Delaloge S; Parent D; Madranges N; Levy C; Dalenc F; Brain E; Uwer L; D'Hondt V; Augereau P; Mailliez A; Perrin C; Frenel JS; Sablin MP; Mouret-Reynier MA; Vermeulin T; Eymard JC; Petit T; Ferrero JM; Ilie S; Goncalves A; Chenuc G; Robain M; Simon G; Perol D
Anticancer Res; 2020 Jul; 40(7):3905-3913. PubMed ID: 32620631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
